Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexanian

Showing results (171-180 of 371) with videos related to

Pageof 38
Sort By:
Stem Cells (Dayton, Ohio)|August 1, 1995
Myeloablative therapy for primary resistant multiple myelomaR Alexanian, M A Dimopoulos, K B Delasalle, et al.
The American Journal of Medicine|January 1, 1993
Risk of disease progression in asymptomatic multiple myelomaM A Dimopoulos, A Moulopoulos, T Smith, et al.
Cytotherapy|August 26, 2010
Transplantation of human glial-restricted neural precursors into injured spinal cord promotes functional and sensory recovery without causing allodyniaArshak R Alexanian, Clive N Svendsen, Maria J Crowe, et al.
Cancer|April 15, 1981
Chemoimmunotherapy for multiple myelomaR Alexanian, S Salmon, J Gutterman, et al.
Dermatology Online Journal|March 14, 2019
Verrucous melanoma masquerading as a seborrheic keratosisPatrick T Tran, Allison K Truong, William Munday, et al.
Blood|January 15, 1994
Limited value of myeloablative therapy for late multiple myelomaR Alexanian, M Dimopoulos, T Smith, et al.
Current Diabetes Reports|March 10, 2016
Stress Hyperglycemia During Surgery and Anesthesia: Pathogenesis and Clinical ImplicationsNadine E Palermo, Roma Y Gianchandani, Marie E McDonnell, et al.
Journal of the American Chemical Society|March 10, 2018
A General Strategy for Aliphatic C-H Functionalization Enabled by Organic Photoredox CatalysisKaila A Margrey, William L Czaplyski, David A Nicewicz, et al.
Seminars in Hematology|March 16, 2004
Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, et al.
Stem Cells and Development|May 20, 2008
In vitro and in vivo characterization of neurally modified mesenchymal stem cells induced by epigenetic modifiers and neural stem cell environmentArshak R Alexanian, Dennis J Maiman, Shekar N Kurpad, et al.
Pageof 38

Showing results (171-180 of 371) with videos related to

Sort By:
Pageof 38
Stem Cells (Dayton, Ohio)|August 1, 1995
Myeloablative therapy for primary resistant multiple myelomaR Alexanian, M A Dimopoulos, K B Delasalle, et al.
The American Journal of Medicine|January 1, 1993
Risk of disease progression in asymptomatic multiple myelomaM A Dimopoulos, A Moulopoulos, T Smith, et al.
Cytotherapy|August 26, 2010
Transplantation of human glial-restricted neural precursors into injured spinal cord promotes functional and sensory recovery without causing allodyniaArshak R Alexanian, Clive N Svendsen, Maria J Crowe, et al.
Cancer|April 15, 1981
Chemoimmunotherapy for multiple myelomaR Alexanian, S Salmon, J Gutterman, et al.
Dermatology Online Journal|March 14, 2019
Verrucous melanoma masquerading as a seborrheic keratosisPatrick T Tran, Allison K Truong, William Munday, et al.
Blood|January 15, 1994
Limited value of myeloablative therapy for late multiple myelomaR Alexanian, M Dimopoulos, T Smith, et al.
Current Diabetes Reports|March 10, 2016
Stress Hyperglycemia During Surgery and Anesthesia: Pathogenesis and Clinical ImplicationsNadine E Palermo, Roma Y Gianchandani, Marie E McDonnell, et al.
Journal of the American Chemical Society|March 10, 2018
A General Strategy for Aliphatic C-H Functionalization Enabled by Organic Photoredox CatalysisKaila A Margrey, William L Czaplyski, David A Nicewicz, et al.
Seminars in Hematology|March 16, 2004
Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, et al.
Stem Cells and Development|May 20, 2008
In vitro and in vivo characterization of neurally modified mesenchymal stem cells induced by epigenetic modifiers and neural stem cell environmentArshak R Alexanian, Dennis J Maiman, Shekar N Kurpad, et al.
Pageof 38